Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients

Jurjen tel; Erik H. J. G. Aarntzen; Tetsuro Baba; Gerty Schreibelt; Barbara M. Schulte; Daniel Benitez-Ribas; Otto C. Boerman; Sandra Croockewit; Wim J. G. Oyen; Michelle van Rossum; Gregor Winkels; Pierre G. Coulie; Cornelis J. A. Punt; Carl G. Figdor; I. Jolanda M. de Vries

doi:https://doi.org/10.1158/0008-5472.CAN-12-2583

Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients

Jurjen tel, Erik H. J. G. Aarntzen, Tetsuro Baba, Gerty Schreibelt, Barbara M. Schulte, Daniel Benitez-Ribas, Otto C. Boerman, Sandra Croockewit, Wim J. G. Oyen, Michelle van Rossum, Gregor Winkels, Pierre G. Coulie, Cornelis J. A. Punt, Carl G. Figdor, I. Jolanda M. de Vries

Research output: Contribution to journal › Article › Academic › peer-review

280 Citations (Scopus)

Abstract

Vaccination against cancer by using dendritic cells has for more than a decade been based on dendritic cells generated ex vivo from monocytes or CD34(+) progenitors. Here, we report on the first clinical study of therapeutic vaccination against cancer using naturally occurring plasmacytoid dendritic cells (pDC). Fifteen patients with metastatic melanoma received intranodal injections of pDCs activated and loaded with tumor antigen-associated peptides ex vivo. In vivo imaging showed that administered pDCs migrated and distributed over multiple lymph nodes. Several patients mounted antivaccine CD4(+) and CD8(+) T-cell responses. Despite the limited number of administered pDCs, an IFN signature was observed after each vaccination. These results indicate that vaccination with naturally occurring pDC is feasible with minimal toxicity and that in patients with metastatic melanoma, it induces favorable immune responses

Original language	English
Pages (from-to)	1063-1075
Journal	Cancer research
Volume	73
Issue number	3
DOIs	https://doi.org/10.1158/0008-5472.CAN-12-2583
Publication status	Published - 2013

Access to Document

https://doi.org/10.1158/0008-5472.CAN-12-2583

Cite this

tel, J., Aarntzen, E. H. J. G., Baba, T., Schreibelt, G., Schulte, B. M., Benitez-Ribas, D., Boerman, O. C., Croockewit, S., Oyen, W. J. G., van Rossum, M., Winkels, G., Coulie, P. G., Punt, C. J. A., Figdor, C. G., & de Vries, I. J. M. (2013). Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer research, 73(3), 1063-1075. https://doi.org/10.1158/0008-5472.CAN-12-2583

@article{39de2e8be6604611abdeabd2f2409404,

title = "Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients",

abstract = "Vaccination against cancer by using dendritic cells has for more than a decade been based on dendritic cells generated ex vivo from monocytes or CD34(+) progenitors. Here, we report on the first clinical study of therapeutic vaccination against cancer using naturally occurring plasmacytoid dendritic cells (pDC). Fifteen patients with metastatic melanoma received intranodal injections of pDCs activated and loaded with tumor antigen-associated peptides ex vivo. In vivo imaging showed that administered pDCs migrated and distributed over multiple lymph nodes. Several patients mounted antivaccine CD4(+) and CD8(+) T-cell responses. Despite the limited number of administered pDCs, an IFN signature was observed after each vaccination. These results indicate that vaccination with naturally occurring pDC is feasible with minimal toxicity and that in patients with metastatic melanoma, it induces favorable immune responses",

author = "Jurjen tel and Aarntzen, {Erik H. J. G.} and Tetsuro Baba and Gerty Schreibelt and Schulte, {Barbara M.} and Daniel Benitez-Ribas and Boerman, {Otto C.} and Sandra Croockewit and Oyen, {Wim J. G.} and {van Rossum}, Michelle and Gregor Winkels and Coulie, {Pierre G.} and Punt, {Cornelis J. A.} and Figdor, {Carl G.} and {de Vries}, {I. Jolanda M.}",

year = "2013",

doi = "https://doi.org/10.1158/0008-5472.CAN-12-2583",

language = "English",

volume = "73",

pages = "1063--1075",

journal = "Cancer research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "3",

}

tel, J, Aarntzen, EHJG, Baba, T, Schreibelt, G, Schulte, BM, Benitez-Ribas, D, Boerman, OC, Croockewit, S, Oyen, WJG, van Rossum, M, Winkels, G, Coulie, PG, Punt, CJA, Figdor, CG & de Vries, IJM 2013, 'Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients', Cancer research, vol. 73, no. 3, pp. 1063-1075. https://doi.org/10.1158/0008-5472.CAN-12-2583

TY - JOUR

T1 - Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients

AU - tel, Jurjen

AU - Aarntzen, Erik H. J. G.

AU - Baba, Tetsuro

AU - Schreibelt, Gerty

AU - Schulte, Barbara M.

AU - Benitez-Ribas, Daniel

AU - Boerman, Otto C.

AU - Croockewit, Sandra

AU - Oyen, Wim J. G.

AU - van Rossum, Michelle

AU - Winkels, Gregor

AU - Coulie, Pierre G.

AU - Punt, Cornelis J. A.

AU - Figdor, Carl G.

AU - de Vries, I. Jolanda M.

PY - 2013

Y1 - 2013

N2 - Vaccination against cancer by using dendritic cells has for more than a decade been based on dendritic cells generated ex vivo from monocytes or CD34(+) progenitors. Here, we report on the first clinical study of therapeutic vaccination against cancer using naturally occurring plasmacytoid dendritic cells (pDC). Fifteen patients with metastatic melanoma received intranodal injections of pDCs activated and loaded with tumor antigen-associated peptides ex vivo. In vivo imaging showed that administered pDCs migrated and distributed over multiple lymph nodes. Several patients mounted antivaccine CD4(+) and CD8(+) T-cell responses. Despite the limited number of administered pDCs, an IFN signature was observed after each vaccination. These results indicate that vaccination with naturally occurring pDC is feasible with minimal toxicity and that in patients with metastatic melanoma, it induces favorable immune responses

AB - Vaccination against cancer by using dendritic cells has for more than a decade been based on dendritic cells generated ex vivo from monocytes or CD34(+) progenitors. Here, we report on the first clinical study of therapeutic vaccination against cancer using naturally occurring plasmacytoid dendritic cells (pDC). Fifteen patients with metastatic melanoma received intranodal injections of pDCs activated and loaded with tumor antigen-associated peptides ex vivo. In vivo imaging showed that administered pDCs migrated and distributed over multiple lymph nodes. Several patients mounted antivaccine CD4(+) and CD8(+) T-cell responses. Despite the limited number of administered pDCs, an IFN signature was observed after each vaccination. These results indicate that vaccination with naturally occurring pDC is feasible with minimal toxicity and that in patients with metastatic melanoma, it induces favorable immune responses

U2 - https://doi.org/10.1158/0008-5472.CAN-12-2583

DO - https://doi.org/10.1158/0008-5472.CAN-12-2583

M3 - Article

C2 - 23345163

SN - 0008-5472

VL - 73

SP - 1063

EP - 1075

JO - Cancer research

JF - Cancer research

IS - 3

ER -